Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.45 |
| ▸ | NOS1 | P29475 | 10/20 | 0.45 |
| ▸ | NOS3 | P29474 | 7/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666234 | 0.86 | NOS2 (0.52) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4863062 | 0.83 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4867936 | 0.82 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4871273 | 0.81 | NOS2 (0.53) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4867916 | 0.79 | NOS2 (0.46) | NOS2NOS1NOS3CYP2C9CNR1 | |
| SCHEMBL4666236 | 0.79 | NOS2 (0.48) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4864599 | 0.79 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4866627 | 0.78 | NOS2 (0.46) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4867989 | 0.78 | NOS2 (0.56) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4866623 | 0.78 | NOS2 (0.45) | NOS2NOS1NOS3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | claimed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | claimed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | claimed |
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.